DGAP-News 1010 0 Kommentare ImevaX welcomes KfW to investor syndicate in second closing of Series A financing - Seite 2

diseases. The financing is an essential contribution to the development of
our lead candidate IMX101 through first clinical proof of efficacy studies
and potentially into partnering discussions."

About ImevaX:
ImevaX is a biopharmaceutical company founded in 2014 based in Munich,
Germany. The focus is to combat chronic and nosocomial infections by
creating specific vaccines. The company's lead candidate IMX101 is a
vaccine against Helicobacter pylori (H. pylori), which colonizes the
stomach and is the cause of ulcer disease and gastric cancer in humans.
Founder Markus Gerhard and his team discovered that the colonization
ability (and hence, the infectiousness) of H. pylori depends on a secreted
bacterial factor that down-regulates the host immune system. Many other
highly infectious pathogens have evolved similar immune evasion mechanisms,
which are the focus of the ImevaX screening program. For more information
please visit: www.imevax.com

About KfW:
Since its foundation in 1948, KfW has become one of the World's leading
promotional banks. KfW Group supports change and encourages forward-looking
ideas in Germany, Europe and throughout the world. In 2014, KfW Group
committed to a total EUR 74.1 billion of investments, focusing mainly on
small and medium-sized businesses, environmental and climate protection.
For more information please visit: https://www.kfw.de/kfw.de-2.html

For further information, please contact:



Volker Wedershoven                     Katja Arnold (CIRO)
Chief Executive Officer                Executive Director
ImevaX GmbH                            MC Services AG
Tel: +49 (0) 89 41 424 55 0            Tel: +49 (0) 89 210 228 40
Email: volker.wedershoven@imevax.com   Email: katja.arnold@mc-services.eu

---------------------------------------------------------------------

02.03.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------

327959 02.03.2015

Seite 2 von 2

◄ Seite 1